WT1-antigen specific TCR-gene transduced T lymphocytes transfer using MS3-WT1-siTCR vector for acute myelogeneous leukaemia and myelodysplastic syndrome

Trial Profile

WT1-antigen specific TCR-gene transduced T lymphocytes transfer using MS3-WT1-siTCR vector for acute myelogeneous leukaemia and myelodysplastic syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs WT1 TCR-transduced T cells-Takara Bio (Primary) ; WT1 peptide vaccine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man
  • Sponsors Takara Bio
  • Most Recent Events

    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 25 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top